Impact Of Billion Dollar Deal Between Celgene Corporation (NASDAQ:CELG) And Juno Therapeutics Inc (NASDAQ:JUNO) On Biotech Market

Celgene Corporation (NASDAQ:CELG) announced yesterday that it will spend roughly $1 billion to venture into a partnership with Juno Therapeutics Inc (NASDAQ:JUNO). The two firms will engage in a ten-year partnership that is expected to keep the biotech bull market going. Celgene maintains that the deal is in the best interest of the company, regardless […]

GlaxoSmithKline plc (ADR) (NYSE:GSK) Bankrolls A Tiny Startup In Search Of An HIV Cure

GlaxoSmithKline plc (ADR) (NYSE:GSK) will team up with the University of North Carolina to form a spinoff that will initially put all its focus on the search for a cure for HIV. The company has been experiencing some rough times and will allocate some of its resources to the joint venture that it hopes will […]

Eli Lilly and Co (NYSE:LLY) Opens a Facility At Cambridge

Eli Lilly and Co (NYSE:LLY) is looking to Cambridge to jump start its innovation engine. The company will be building a new R&D facility on the Charles River becoming the latest company to make the move. The new facility is named Lilly Cambridge Innovation Center and will start by the end of the year Kendall […]

GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets

On Wednesday, GlaxoSmithKline plc (ADR) (NYSE:GSK) divulged its growth goals. This is an endeavor to persuade investors that concentrating on consumer health and vaccines would bring back long-term growth. It also discarded plans to float its HIV drug business ViiV Healthcare pointing to its strong outlook. Further, it pledged to disburse a regular dividend of […]

FDA Clears The Way For Arrowhead Research Corp (NASDAQ:ARWR) Hep B Treatment, With A Caveat

Arrowhead Research Corp (NASDAQ:ARWR) has finally been given the go ahead sign to beggin its phase II B trials of ARC 520. The company will now be able to further its research on the Hepatitis B treatment courtesy of the FDA. Despite the approval, the company still has to persuade other supervisory bodies before it […]

Receptos Inc (NASDAQ:RCPT) Raising Funds For Product Development

Boston, MA 06/19/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) has turned to equity offering to raise funds for the development of its lead drug candidate PRC1063 and others. The drug is going through Phase III trial after showing compelling results in its Phase II study. The treatment targets multiple sclerosis (MS). The company has announced offering of […]

Glaxo SmithKline plc (ADR) (NYSE:GSK) Strikes Deal On Cancer Drug Venture

Boston, MA 06/04/2014 (wallstreetpr) – Developer and manufacturer of global healthcare products, Glaxo SmithKline plc (ADR) (NYSE:GSK) has struck a deal with biotechnology and privately-held company, Adaptimmune, for the development of a drug for cancer. Cancer Drug Glaxo SmithKline’s deal with Adaptimmune is reportedly worth over $350 million that is spread over a period of […]

Pfizer Inc. (NYSE:PFE) Charts New Path After Failed Bid For Astrazeneca Plc (ADR) (NYSE:AZN)

Boston, MA 06/02/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) has promised to move on after failing to win the nod of the board of directors of Astrazeneca Plc (ADR) (NYSE:AZN) for a tie-up deal. Although the company still has an opportunity to make another bid for Astrazeneca after six months, according to the U.K. Takeover Code, Pfizer […]

Competition Stricken Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) May Look For India Deal Despite Denial

Boston, MA 05/23/2014 (wallstreetpr) – The Israel-based drug company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has taken several doses of its own medicine in recent times. The company that thrives in developing and marketing generic drugs has in recent times until last week tried to stop competitors from developing a copycat of its bestselling Copaxone […]

Ophthotech Corp (NASDAQ:OPHT) Reaches Deal With Novartis AG (ADR) (NYSE:NVS) On Fovista

Boston, MA 05/20/2014 (wallstreetpr) – Developer of novel therapeutics, Ophthotech Corp (NASDAQ:OPHT) announced that it has struck a deal with the German-based Novartis AG (ADR) (NYSE:NVS) on licensing and commercialization of drug, Fovista, outside the U.S. Deal on Fovista The agreement struck between the two companies allows Ophthotech to grant exclusive rights to Novartis to commercialize […]

Disappointed Novartis AG (ADR) (NYSE:NVS) Looks To Building New Evidence Around Rejected Heart Drug

Boston, MA 05/19/2014 (wallstreetpr) – Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) suffered a rejection in the hands of the U.S. Food and Drug Administration (FDA) that declined to approved its much-touted heart failure medication, serelaxin or RLX030. However, the company said it will push forward with efforts to bring the drug to the market as […]

Novartis AG (ADR) (NYSE:NVS) Achieve Another Milestone

Boston, MA 05/16/2014 (wallstreetpr) – Novartis AG (ADR) (NYSE:NVS) reported that Signifor LAR achieved a positive result in its Phase III study to treat acromegaly patients. Signifor study The study proved that the patients having Signifor LAR have superior efficacy than the available standard therapy (Somatostatin analogues). Based on the results, Novartis will proceed to […]

Novartis AG (ADR) (NYSE:NVS) Settles Patent Litigation With the U.S. Subsidiary Of Sun Pharmaceutical

Boston, MA 05/15/2014 (wallstreetpr) – The Switzerland-based drug giant Novartis AG (ADR) (NYSE:NVS) has reached another milestone with the latest patent litigation settlement in the U.S.  The company reached a settlement with the U.S. subsidiary of Sun Pharmaceutical Industries.  The agreement touches on the development of a generic version of Gleevec, a patented prescription drug […]

In The Wake Of High Healthcare Costs, Novartis AG (ADR) (NYSE:NVS), Roche Become Targets

Boston, MA 05/08/2014 (wallstreetpr) – Novartis AG (ADR) (NYSE:NVS) and fellow drug company Roche are facing scrutiny from the European authorities over possible collusion in the marketing of two drugs. The two companies are already being investigated in a number of countries in Europe over the same concerns. Italy and France have had issues with […]

Novartis AG (ADR) (NYSE:NVS) Reverses Gear On Acquisition Deal

Boston, MA 05/05/2014 (wallstreetpr) – The Swiss-based Novartis AG (ADR) (NYSE:NVS) was due to acquire the ownership of Jerusalem-based Gamida Cell, a stem cell technology company. However, that transaction is off, according to the parent companies of Gamida. Novartis was planned to take over the full ownership of Gamida in a sale transaction valued at $600 […]